US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

8.40

-0.5400-6.04%

Post-market: 8.500.1000+1.19%19:16 EDT

Volume:1.39M

Turnover:12.03M

Market Cap:262.84M

PE:-2.95

High:9.25

Open:8.90

Low:8.40

Close:8.94

52wk High:50.40

52wk Low:8.40

Shares:31.29M

Float Shares:15.69M

Volume Ratio:0.67

T/O Rate:8.88%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8500

EPS(LYR):-2.8503

ROE:-33.63%

ROA:-21.86%

PB:0.92

PE(LYR):-2.95

Loading ...

Overview Company News Filings

Buy Rating on Structure Therapeutics: Aleniglipron’s Strengthening Clinical Profile and Undervalued Global Obesity Opportunity

OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate? -- Barrons.com

Outlook Therapeutics Refinances Debt, Extends Note Maturities

Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%

Benzinga_recent_news

Spyre Therapeutics completes recruitment for SKYWAY basket trial sub-study

Aprea Therapeutics Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $3.337K Down From $205.817K YoY

Press Release: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

Press Release: Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

OnKure Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Ernexa Therapeutics files $50M mixed securities shelf

OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright

Summit Therapeutics downgraded to Hold from Buy at Jefferies

PYC Therapeutics Agrees on Framework for Registrational Study Design for Blinding Eye Disease Drug Candidate New Drug Application

MT Newswires Live

Percheron Therapeutics Plans Large Pro Rata Capital Raising on ASX

Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%

MT Newswires Live

Cutia Therapeutics Wins China Trial Nod for New Topical Hair-Loss Drug

Percheron Therapeutics Launches Discounted Entitlement Offer to Fund HMBD-002 Trial

Plus Therapeutics: Advancing Reyobiq Pipeline and CNSide Commercialization Underpinned by Strong Cash Runway to 2027

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=13"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":8.4,"timestamp":1774641600000,"preClose":8.94,"halted":0,"volume":1393631,"hourTrading":{"tag":"盘后","latestPrice":8.5,"preClose":8.4,"latestTime":"19:16 EDT","volume":25181,"amount":211529.72,"timestamp":1774653413550,"change":0.1,"changeRate":0.011905,"amplitude":0.011905},"delay":0,"changeRate":-0.060402684563758295,"floatShares":15692500,"shares":31289969,"eps":-2.85,"marketStatus":"Market Closed","change":-0.54,"latestTime":"03-27 16:00:00 EDT","open":8.9,"high":9.25,"low":8.395,"amount":12026989.540177,"amplitude":0.095638,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.85,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":8.94,"preHourTrading":{"tag":"盘前","latestPrice":8.95,"preClose":8.94,"latestTime":"09:25 EDT","volume":2891,"amount":25925.149467,"timestamp":1774617913255,"change":0.01,"changeRate":0.001119,"amplitude":0.016779},"postHourTrading":{"tag":"盘后","latestPrice":8.5,"preClose":8.4,"latestTime":"19:16 EDT","volume":25181,"amount":211529.72,"timestamp":1774653413550,"change":0.1,"changeRate":0.011905,"amplitude":0.011905},"volumeRatio":0.670644,"impliedVol":1.3191,"impliedVolPercentile":0.9877},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":15692500,"roa":"-21.86%","roe":"-33.63%","lyrEps":-2.850329,"volumeRatio":0.670644,"shares":31289969,"dividePrice":0,"high":9.25,"amplitude":0.095638,"preClose":8.94,"low":8.395,"week52Low":8.395,"pbRate":"0.92","psRate":"13.77","week52High":50.4,"institutionHeld":0,"latestPrice":8.4,"eps":-2.85,"divideRate":0,"volume":1393631,"delay":0,"ttmEps":-2.85,"open":8.9,"prevYearClose":16,"prevWeekClose":10.48,"prevMonthClose":13.49,"prevQuarterClose":16,"fiveDayClose":10.48,"twentyDayClose":13.49,"sixtyDayClose":16.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59},{"market":"US","date":"2025-07-30","symbol":"LENZ","fiscalQuarterEnding":"2025/06","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-03-27","current":-2.947368,"percent":1,"low":-26.69966,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"high":-3.413108,"avg":-12.467749,"sd":5.207963,"marketCap":280308282},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282}],"updateTime":1774706646997},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:13,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620467352","title":"Buy Rating on Structure Therapeutics: Aleniglipron’s Strengthening Clinical Profile and Undervalued Global Obesity Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2620467352","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620467352?lang=en_us&edition=fundamental","pubTime":"2026-03-16 23:55","pubTimestamp":1773676515,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh has reiterated their bullish stance on GPCR stock, giving a Buy rating today. Andy Hsieh has given his Buy rating ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-structure-therapeutics-alenigliprons-strengthening-clinical-profile-and-undervalued-global-obesity-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-structure-therapeutics-alenigliprons-strengthening-clinical-profile-and-undervalued-global-obesity-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2619264464","title":"OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2619264464","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619264464?lang=en_us&edition=fundamental","pubTime":"2026-03-16 22:55","pubTimestamp":1773672922,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their bullish stance on OKUR stock, giving a Buy rating on March 13. Soumit Roy has given his Buy ra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/onkure-therapeutics-positive-view-on-oki-219-ahead-of-pikture-1-breast-cancer-data-as-key-upside-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/onkure-therapeutics-positive-view-on-oki-219-ahead-of-pikture-1-breast-cancer-data-as-key-upside-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"2619545464","title":"Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate? -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2619545464","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619545464?lang=en_us&edition=fundamental","pubTime":"2026-03-16 22:46","pubTimestamp":1773672360,"startTime":"0","endTime":"0","summary":"The biotech firm Structure Therapeutics said its GLP-1 pill helped patients lose over 16% of their weight, on average, in a 10-month drug trial. Weight loss continued the longer patients took the pill, with no plateau in sight, the company said.That's more weight loss than was achieved in studies of the Wegovy pill that Novo Nordisk began marketing in January, or a pill that Eli Lilly is expected to launch soon. In premarket trading Monday, Structure stock was up 10%, to $59.Monday's results were for two high doses of Structure's pill, aleniglipron. The company previously reported weight loss of 15% on a lower dose. Monday's announcement said that patients who'd remained on that lower dose lost up to 16% of their weight in 53 weeks. Side effects and dropouts from the studies were in line with those of most GLP-1 drugs, Structure said.These Phase 2 results will help Structure decide the dose to use when it begins a Phase 3 trial in the second half of this year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4588","GPCR","BK4539","BK4139","BK4007","BK4581","LENZ","BK4585","XBI"],"gpt_icon":0},{"id":"2619985469","title":"Outlook Therapeutics Refinances Debt, Extends Note Maturities","url":"https://stock-news.laohu8.com/highlight/detail?id=2619985469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619985469?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:50","pubTimestamp":1773669035,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Outlook Therapeutics ( ($OTLK) ). On March 16, 2026, Outlook Therapeutics entered into a Note Purchase Agreemen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-refinances-debt-extends-note-maturities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-refinances-debt-extends-note-maturities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2619662024","title":"Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619662024","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619662024?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:27","pubTimestamp":1773667620,"startTime":"0","endTime":"0","summary":"Structure Therapeutics' Phase 2 ACCESS II trial shows up to 16.3% placebo-adjusted weight loss for obesity drug aleniglipron.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/16/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/16/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51268488/structure-therapeutics-stock-explodes-as-much-awaited-experimental-oral-drug-trial-shows-weight-loss-of-16","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51268488/structure-therapeutics-stock-explodes-as-much-awaited-experimental-oral-drug-trial-shows-weight-loss-of-16","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","BK4007","BK4539","BK4217","SMA","LENZ"],"gpt_icon":0},{"id":"2619583463","title":"Spyre Therapeutics completes recruitment for SKYWAY basket trial sub-study","url":"https://stock-news.laohu8.com/highlight/detail?id=2619583463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619583463?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:39","pubTimestamp":1773664779,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced the completion of recruitment for the RA sub-study of the SKYWAY basket trial and acceleration of expected topl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-completes-recruitment-for-skyway-basket-trial-sub-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-completes-recruitment-for-skyway-basket-trial-sub-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","BK4539","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2619450030","title":"Aprea Therapeutics Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $3.337K Down From $205.817K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450030","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450030?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:11","pubTimestamp":1773663083,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 5.61 percent. This is a 34.69 percent increase over losses of $(0.49) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51266221/aprea-therapeutics-q4-eps-0-32-misses-0-30-estimate-sales-3-337k-down-from-205-817k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2619450024","title":"Press Release: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450024?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., March 16, 2026  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC  and the issuance of a new non-convertible, unsecured note with Atlas Sciences, LLC .Under the amendment to the Existing Note, the maturity date of the Existing Note has been extended to December 31, 2026, with no other changes to the terms. The lender has confirmed that the Existing Note is not in default.In addition, Outlook Therapeutics entered into the $18.4 million New Note. The Company expects to receive $17 million in net proceeds, after original issue discount. Proceeds from the New Note will be used to pay down a portion of the Existing Note, reducing the balance and leaving approximately $10.8 million of principal and interest remaining on the Existing Note.The New Note bears interest at a rate equal to th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4573","LU0109392836.USD","AMYY","LU1316542783.SGD","LU0889565833.HKD","BK4529","LU1242518931.SGD","LU2931357623.SGD","BK4566","LU1951200564.SGD","IE00BMPRXN33.USD","LU0082616367.USD","LU0056508442.USD","03160","LU1989764664.SGD","OTLK","TM","DAMD","AMDL","BK4612","BK4007","AMDU","AMDD","AMDY","LU0390134368.USD","LU2355687059.USD","LENZ","LU1951198990.SGD","AMUU","BK4604","BK4554","AMDW","LU2458330243.SGD","LU1923623000.USD","LU1880398471.USD","BK4512","LU0719512351.SGD","LU1880398554.USD","LU1988902786.USD","BK4543","BK4588","LU2098885051.SGD","BK4141","LU1064131342.USD","LU0823421333.USD","LU2458330169.SGD","BK4539","BK4534","AMDG"],"gpt_icon":1},{"id":"2619500464","title":"Press Release: Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619500464","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619500464?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:00","pubTimestamp":1773662400,"startTime":"0","endTime":"0","summary":"Coya Therapeutics, Inc.  , a clinical-stage biotechnology company developing biologics intended to enhance T-cell  function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the year ended December 31, 2025.--  Successfully launched the ALSTARS Phase 2 trial evaluating COYA. 302 for the treatment of ALS and now actively enrolling and dosing. patients across 25 clinical sites in the U.S. and Canada.--  Clinical Trial Application  acceptance from Health Canada. to proceed with the COYA 302 ALSTARS Phase 2 trial in Canada.--  Announced COYA 302 ALS trial acceptance by NEALS as a. --  Announced U.S. FDA acceptance of Investigation New Drug . Application for COYA 302 for the treatment of frontotemporal. and brain anti-inflammatory activity and enhanced Treg cell. function in an in vivo lipopolysaccharide  preclinical mouse. --  Published results in Frontiers in Immunology linking. inflammation and oxidative stress to the progre","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CTA","COYA","LENZ","BK4539","IND"],"gpt_icon":0},{"id":"2619425463","title":"Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619425463","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619425463?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:00","pubTimestamp":1773662400,"startTime":"0","endTime":"0","summary":"Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutationClinical team","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256191/0/en/Aprea-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BK4539","LENZ"],"gpt_icon":0},{"id":"2619457010","title":"OnKure Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457010","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457010?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:30","pubTimestamp":1773660600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKUR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 07:30 ET (11:30 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2619545253","title":"Ernexa Therapeutics files $50M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2619545253","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619545253?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:56","pubTimestamp":1773658594,"startTime":"0","endTime":"0","summary":"06:51 EDT Ernexa Therapeutics (ERNA) files $50M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-files-50m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-files-50m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","ERNA","LENZ","BK4139"],"gpt_icon":0},{"id":"2619045111","title":"OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2619045111","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619045111?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:15","pubTimestamp":1773656140,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on OnKure Therapeutics (OKUR) to $27 from $34 and keeps a Buy rating on the shares post the Q4 repo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onkure-therapeutics-price-target-lowered-to-27-from-34-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onkure-therapeutics-price-target-lowered-to-27-from-34-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2619456397","title":"Summit Therapeutics downgraded to Hold from Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2619456397","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619456397?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:15","pubTimestamp":1773652505,"startTime":"0","endTime":"0","summary":"Jefferies downgraded Summit Therapeutics (SMMT) to Hold from Buy with a price target of $15, down from $42, after assuming coverage of the name. Su...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-downgraded-to-hold-from-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-downgraded-to-hold-from-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","SMMF"],"gpt_icon":0},{"id":"2619487105","title":"PYC Therapeutics Agrees on Framework for Registrational Study Design for Blinding Eye Disease Drug Candidate New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2619487105","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619487105?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:57","pubTimestamp":1773626256,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  agreed with the US Food and Drug Administration  on a framework for the design of a registrational study intended to support a new drug application for drug candidate VP-001 in retinitis pigmentosa type 11 , according to a Monday filing with the Australian bourse.The company and the US FDA agreed on the nomination of the primary endpoint, the nomination and ranking of key secondary endpoints, as well as the nomination of other secondary endpoints, the filing said.The FDA also confirmed that the company can incorporate natural history data from its study on RP11 patients with the randomized sham control arm data from the proposed registrational trial as part of the new drug application submission, per the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK7067","PYC.AU","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2619487291","title":"Percheron Therapeutics Plans Large Pro Rata Capital Raising on ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2619487291","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619487291?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:47","pubTimestamp":1773625635,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics ( ($AU:PER) ) has issued an announcement. Percheron Therapeutics has announced a proposed non-renounceable pro rata offer to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-plans-large-pro-rata-capital-raising-on-asx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-plans-large-pro-rata-capital-raising-on-asx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2619484594","title":"Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619484594","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619484594?lang=en_us&edition=fundamental","pubTime":"2026-03-16 08:40","pubTimestamp":1773621622,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said Michael Thurn has resigned as managing director and chief executive officer, stepping down from his executive responsibilities from March 16, with his contractual notice period concluding in July 2026, according to a Monday Australian bourse filing.Thurn will continue to serve as a non-executive director until the completion of his notice period, the filing added.The company said Sergio Duchini will assume the role of interim executive chair until a suitable chief executive is appointed, while a global search for a new CEO is underway with the assistance of executive search firm Coulter Partners.The company's shares fell 13% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4007","BK7096","LENZ","NUZ.AU","BK4139"],"gpt_icon":0},{"id":"2619848127","title":"Cutia Therapeutics Wins China Trial Nod for New Topical Hair-Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2619848127","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619848127?lang=en_us&edition=fundamental","pubTime":"2026-03-16 08:07","pubTimestamp":1773619635,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics ( ($HK:2487) ) has issued an announcement. Cutia Therapeutics has received clinical trial approval from China’s National Medical...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cutia-therapeutics-wins-china-trial-nod-for-new-topical-hair-loss-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cutia-therapeutics-wins-china-trial-nod-for-new-topical-hair-loss-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"2619894434","title":"Percheron Therapeutics Launches Discounted Entitlement Offer to Fund HMBD-002 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2619894434","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619894434?lang=en_us&edition=fundamental","pubTime":"2026-03-16 07:24","pubTimestamp":1773617076,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics ( ($AU:PER) ) has shared an announcement. Percheron Therapeutics has launched a 2-for-5 non-renounceable entitlement offer t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-launches-discounted-entitlement-offer-to-fund-hmbd-002-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-launches-discounted-entitlement-offer-to-fund-hmbd-002-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2619120130","title":"Plus Therapeutics: Advancing Reyobiq Pipeline and CNSide Commercialization Underpinned by Strong Cash Runway to 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2619120130","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619120130?lang=en_us&edition=fundamental","pubTime":"2026-03-15 02:05","pubTimestamp":1773511538,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Plus Therapeutics, retaining the price target of $1.50. Jason McCarthy has given h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/plus-therapeutics-advancing-reyobiq-pipeline-and-cnside-commercialization-underpinned-by-strong-cash-runway-to-2027-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/plus-therapeutics-advancing-reyobiq-pipeline-and-cnside-commercialization-underpinned-by-strong-cash-runway-to-2027-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":13,"totalSize":260,"code":"91000000","status":"200"}]}}